Improving Influenza Vaccination Coverage in Patients with Cancer: A Position Paper from a Multidisciplinary Expert Group
Abstract
:1. Introduction
2. Materials and Methods
3. Annual Vaccination Plans and Influenza Vaccines
4. Influenza Vaccination for Patients with Cancer
4.1. Rationale and Evidence
4.2. Current Recommendations
4.3. COVID-19 Vaccination in Patients with Cancer
5. Barriers to Influenza Vaccination
6. Strategies to Overcome Barriers
7. Future Directions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Rodrigues, C.M.C.; Plotkin, S.A. Impact of vaccines; health, economic and social perspectives. Front. Microbiol. 2020, 11, 1526. [Google Scholar] [CrossRef] [PubMed]
- Gupta, G.; Glueck, R.; Patel, P.R. HPV vaccines: Global perspectives. Hum. Vaccin. Immunother. 2017, 13, 6. [Google Scholar] [CrossRef] [PubMed]
- Lundstrom, K. COVID-19 vaccines: Where did we stand at the end of 2023? Viruses 2024, 16, 203. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. WHO Regional Office for Europe Recommendations on Influenza Vaccination for the 2021/2022 Season during the Ongoing COVID-19 Pandemic. Available online: https://www.who.int/europe/publications/i/item/WHO-EURO-2021-3920-43679-61434 (accessed on 5 May 2022).
- Bosaeed, M.; Kumar, D. Seasonal Influenza Vaccine in Immunocompromised Persons. Hum. Vaccin. Immunother. 2018, 14, 1311–1322. [Google Scholar] [CrossRef]
- Shehata, M.A.; Karim, N.A. Influenza vaccination in cancer patients undergoing systemic therapy. Clin. Med. Insights Oncol. 2014, 8, 57–64. [Google Scholar] [CrossRef] [PubMed]
- Cooksley, C.D.; Avritscher, E.B.; Bekele, B.N.; Rolston, K.V.; Geraci, J.M.; Elting, L.S. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 2005, 104, 618–628. [Google Scholar] [CrossRef] [PubMed]
- Pedrazzoli, P.; Baldanti, F.; Donatelli, I.; Castrucci, M.R.; Puglisi, F.; Silvestris, N.; Cinieri, S. Vaccination for seasonal influenza in patients with cancer: Recommendations of the Italian Society of Medical Oncology (AIOM). Ann. Oncol. 2014, 25, 1243–1247. [Google Scholar] [CrossRef]
- Pedrazzoli, P.; Piralla, A.; Valentino, F.; Cinieri, S.; Baldanti, F. Update of the recommendations of the Italian Society of Medical Oncology on vaccination for seasonal influenza and pneumococcal infection in patients with cancer: Focus on prevention of pneumonia. Eur. J. Cancer Care 2018, 27, e12817. [Google Scholar] [CrossRef]
- Pedrazzoli, P.; Baldanti, F.; Cinieri, S.; Bersanelli, M. Raccomandazioni per la Vaccinazione Antinfluenzale e Antipneumococcica in Oncologia. Available online: https://www.aiom.it/wp-content/uploads/2021/01/2021_Racc_vacc_antiinfluenzale_AIOM_agg.pdf (accessed on 5 May 2022).
- Pedrazzoli, P.; Lasagna, A.; Cassaniti, I.; Ferrari, A.; Bergami, F.; Silvestris, N.; Sapuppo, E.; Di Maio, M.; Cinieri, S.; Baldanti, F. Vaccination for herpes zoster in patients with solid tumors: A position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM). ESMO Open 2022, 7, 100548. [Google Scholar] [CrossRef]
- Pedrazzoli, P.; Lasagna, A.; Cassaniti, I.; Piralla, A.; Squeri, A.; Bruno, R.; Sacchi, P.; Baldanti, F.; Di Maio, M.; Beretta, G.D.; et al. Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: Recommendations of the Associazione Italiana di Oncologia Medica (AIOM). ESMO Open 2023, 8, 101215. [Google Scholar] [CrossRef]
- European Centre for Disease Prevention and Control. Seasonal Influenza Vaccination and Antiviral Use in EU/EEA Member States. Available online: https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-antiviral-use-eu-eea-member-states (accessed on 5 May 2022).
- Bersanelli, M.; Giannarelli, D.; Castrignanò, P.; Fornarini, G.; Panni, S.; Mazzoni, F.; Tiseo, M.; Rossetti, S.; Gambale, E.; Rossi, E.; et al. Influenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. The INVIDIa study. Immunotherapy 2018, 10, 1229–1239. [Google Scholar] [CrossRef] [PubMed]
- Wojczyk, M.; Rutecka, P.; Wolak, D.; Zięba, Z.; Zatłoka, D.; Klimas, F.; Wójsik, U.; Wójtowicz, K. Vaccination against influenza and attitudes towards seasonal vaccination of medical students from the Medical University of Silesia. Postepy Hig. Med. Dosw. 2023, 77, 133–142. [Google Scholar] [CrossRef]
- Ng, Q.X.; Lee, D.Y.X.; Ng, C.X.; Yau, C.E.; Lim, Y.L.; Liew, T.M. Examining the negative sentiments related to influenza vaccination from 2017 to 2022: An unsupervised deep learning analysis of 261,613 Twitter posts. Vaccines 2023, 11, 1018. [Google Scholar] [CrossRef] [PubMed]
- Ministero della Salute. Vaccination Calendar. Available online: https://www.salute.gov.it/portale/vaccinazioni/dettaglioContenutiVaccinazioni.jsp?lingua=italiano&id=4829&area=vaccinazioni&menu=vuoto (accessed on 18 March 2024). (In Italian)
- Ministero della Salute. Prevention and Control of Influenza: Recommendations for the 2023–2024 Season. Available online: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2023&codLeg=93294&parte=1%20&serie=null (accessed on 18 March 2024). (In Italian)
- Ministero della Salute. Communication Campaign on Vaccination against COVID and Seasonal Flu. Available online: https://www.salute.gov.it/portale/influenza/dettaglioCampagneInfluenza.jsp?lingua=italiano&menu=campagne&p=dacampagne&id=178 (accessed on 18 March 2024). (In Italian)
- World Health Organization. Vaccines against influenza: WHO Position Paper—May 2022. Wkly Epidemiol. Rec. 2022, 97, 185–208. [Google Scholar]
- World Health Organization. Global Influenza Programme: Recommendations for Influenza Vaccine Composition. Available online: https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations (accessed on 2 August 2022).
- Council of the European Union. Council Recommendation of 22 December 2009 on Seasonal Influenza Vaccination (Text with EEA Relevance). Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32009H1019&qid=1649670283539 (accessed on 18 March 2024).
- Richard, M.; Fouchier, R.A. Influenza A virus transmission via respiratory aerosols or droplets as it relates to pandemic potential. FEMS Microbiol. Rev. 2016, 40, 68–85. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Estimating Disease Burden of Influenza. Available online: https://www.who.int/europe/activities/estimating-disease-burden-of-influenza (accessed on 25 January 2024).
- Iuliano, A.D.; Roguski, K.M.; Chang, H.H.; Muscatello, D.J.; Palekar, R.; Tempia, S.; Cohen, C.; Gran, J.M.; Schanzer, D.; Cowling, B.J.; et al. Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. Lancet 2018, 391, 1285–1300. [Google Scholar] [CrossRef]
- Ludwig, H.; Boccadoro, M.; Moreau, P.; San-Miguel, J.; Cavo, M.; Pawlyn, C.; Zweegman, S.; Facon, T.; Driessen, C.; Hajek, R.; et al. Recommendations for vaccination in multiple myeloma: A consensus of the European Myeloma Network. Leukemia 2021, 35, 31–44. [Google Scholar] [CrossRef] [PubMed]
- Galluzzi, L.; Buque, A.; Kepp, O.; Zitvogel, L.; Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015, 28, 690–714. [Google Scholar] [CrossRef] [PubMed]
- Kuter, D.J. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica 2022, 107, 1243–1263. [Google Scholar] [CrossRef]
- De Kermenguy, F.; Meziani, L.; Mondini, M.; Clemenson, C.; Morel, D.; Deutsch, E.; Robert, C. Radio-induced lymphopenia in the era of anti-cancer immunotherapy. Int. Rev. Cell Mol. Biol. 2023, 378, 1–30. [Google Scholar] [CrossRef]
- Von Lilienfeld-Toal, M.; Berger, A.; Christopeit, M.; Hentrich, M.; Heussel, C.P.; Kalkreuth, J.; Klein, M.; Kochanek, M.; Penack, O.; Hauf, E.; et al. Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. Eur. J. Cancer 2016, 67, 200–212. [Google Scholar] [CrossRef]
- Li, J.; Zhang, D.; Sun, Z.; Bai, C.; Zhao, L. Influenza in hospitalised patients with malignancy: A propensity score matching analysis. ESMO Open 2020, 5, e000968. [Google Scholar] [CrossRef] [PubMed]
- Wong, J.L.; Evans, S.E. Bacterial pneumonia in patients with cancer: Novel risk factors and management. Clin. Chest Med. 2017, 38, 263–277. [Google Scholar] [CrossRef] [PubMed]
- Seo, S.K.; Liu, C.; Dadwal, S.S. Infectious disease complications in patients with cancer. Crit. Care Clin. 2021, 37, 69–84. [Google Scholar] [CrossRef] [PubMed]
- Kodde, C.; Bonsignore, M.; Schöndube, D.; Bauer, T.; Hohenstein, S.; Bollmann, A.; Meier-Hellmann, A.; Kuhlen, R.; Nachtigall, I. Mortality in cancer patients with SARS-CoV-2 or seasonal influenza: An observational cohort study from a German-wide hospital network. Infection 2023, 51, 119–127. [Google Scholar] [CrossRef] [PubMed]
- Atalla, E.; Kalligeros, M.; Mylona, E.K.; Tsikala-Vafea, M.; Shehadeh, F.; Georgakas, J.; Mylonakis, E. Impact of influenza infection among adult and pediatric populations with hematologic malignancy and hematopoietic stem cell transplant: A systematic review and meta-analysis. Clin. Ther. 2021, 43, e66–e85. [Google Scholar] [CrossRef] [PubMed]
- Ángeles-Sistac, D.; Martin-Onraet, A.; Cornejo-Juárez, P.; Volkow, P.; Pérez-Jimenez, C.; Vilar-Compte, D. Influenza in patients with cancer after 2009 pandemic AH1N1: An 8-year follow-up study in Mexico. Influenza Other Respir. Viruses 2020, 14, 196–203. [Google Scholar] [CrossRef] [PubMed]
- Health and Safety Executive. Immunisation Guidelines: Immunisation of Immunocompromised Persons. Available online: https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter3.pdf (accessed on 7 February 2022).
- Monin, L.; Laing, A.G.; Muñoz-Ruiz, M.; McKenzie, D.R.; Del Molino Del Barrio, I.; Alaguthurai, T.; Domingo-Vila, C.; Hayday, T.S.; Graham, C.; Seow, J.; et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study. Lancet Oncol. 2021, 22, 765–778. [Google Scholar] [CrossRef] [PubMed]
- Karlsson, J.; Andreasson, B.; Kondori, N.; Erman, E.; Riesbeck, K.; Hogevik, H.; Wenneras, C. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom’s macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin. Vaccine Immunol. 2011, 18, 969–977. [Google Scholar] [CrossRef]
- Rubin, L.G.; Levin, M.J.; Ljungman, P.; Davies, E.G.; Avery, R.; Tomblyn, M.; Bousvaros, A.; Dhanireddy, S.; Sung, L.; Keyserling, H.; et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis. 2014, 58, e44–e100. [Google Scholar] [CrossRef] [PubMed]
- Ayoola, A.; Sukumaran, S.; Jain, K.; Kumar, R.; Gordon, D.; Honda-Okubo, Y.; Quinn, S.; Roy, A.; Vatandoust, S.; Koczwara, B.; et al. Efficacy of influenza vaccine (Fluvax) in cancer patients on treatment: A prospective single arm, open-label study. Support. Care Cancer 2020, 28, 5411–5417. [Google Scholar] [CrossRef]
- Bayle, A.; Khettab, M.; Lucibello, F.; Chamseddine, A.N.; Goldschmidt, V.; Perret, A.; Ropert, S.; Scotté, F.; Loulergue, P.; Mir, O. Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1. Ann. Oncol. 2020, 31, 959–961. [Google Scholar] [CrossRef] [PubMed]
- Beck, C.R.; McKenzie, B.C.; Hashim, A.B.; Harris, R.C.; Nguyen-Van-Tam, J.S. Influenza vaccination for immunocompromised patients: Systematic review and meta-analysis by etiology. J. Infect. Dis. 2012, 206, 1250–1259. [Google Scholar] [CrossRef]
- Bersanelli, M.; Buti, S.; Banna, G.L.; De Giorgi, U.; Cortellini, A.; Rebuzzi, S.E.; Tiseo, M.; Fornarini, G.; Mazzoni, F.; Panni, S.; et al. Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. Immunotherapy 2020, 12, 151–159. [Google Scholar] [CrossRef] [PubMed]
- Bersanelli, M.; Giannarelli, D.; De Giorgi, U.; Pignata, S.; Di Maio, M.; Clemente, A.; Verzoni, E.; Giusti, R.; Di Napoli, M.; Aprile, G.; et al. INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2). J. Immunother. Cancer 2021, 9, e002619. [Google Scholar] [CrossRef] [PubMed]
- Bitterman, R.; Eliakim-Raz, N.; Vinograd, I.; Zalmanovici Trestioreanu, A.; Leibovici, L.; Paul, M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst. Rev. 2018, 2, CD008983. [Google Scholar] [CrossRef] [PubMed]
- Blanchette, P.S.; Chung, H.; Pritchard, K.I.; Earle, C.C.; Campitelli, M.A.; Buchan, S.A.; Schwartz, K.L.; Crowcroft, N.S.; Gubbay, J.B.; Karnauchow, T.; et al. Influenza vaccine effectiveness among patients with cancer: A population-based study using health administrative and laboratory testing data from Ontario, Canada. J. Clin. Oncol. 2019, 37, 2795–2804. [Google Scholar] [CrossRef] [PubMed]
- Grijalva, C.G.; Zhu, Y.; Williams, D.J.; Self, W.H.; Ampofo, K.; Pavia, A.T.; Stockmann, C.R.; McCullers, J.; Arnold, S.R.; Wunderink, R.G.; et al. Association between hospitalization with community-acquired laboratory-confirmed influenza pneumonia and prior receipt of influenza vaccination. JAMA 2015, 314, 1488–1497. [Google Scholar] [CrossRef] [PubMed]
- Mulder, S.F.; Jacobs, J.F.; Olde Nordkamp, M.A.; Galama, J.M.; Desar, I.M.; Torensma, R.; Teerenstra, S.; Mulders, P.F.; Vissers, K.C.; Punt, C.J.; et al. Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clin. Cancer Res. 2011, 17, 4541–4549. [Google Scholar] [CrossRef] [PubMed]
- Rousseau, B.; Loulergue, P.; Mir, O.; Krivine, A.; Kotti, S.; Viel, E.; Simon, T.; de Gramont, A.; Goldwasser, F.; Launay, O.; et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: The VACANCE study. Ann. Oncol. 2012, 23, 450–457. [Google Scholar] [CrossRef]
- The Academy of Medical Sciences. COVID-19: Preparing for the Future. Looking Ahead to Winter 2021/22 and Beyond. Available online: https://acmedsci.ac.uk/file-download/4747802 (accessed on 5 May 2022).
- Jorgensen, P.; Mereckiene, J.; Cotter, S.; Johansen, K.; Tsolova, S.; Brown, C. How close are countries of the WHO European Region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015. Vaccine 2018, 36, 442–452. [Google Scholar] [CrossRef] [PubMed]
- Bersanelli, M.; Giannarelli, D.; De Giorgi, U.; Pignata, S.; Di Maio, M.; Verzoni, E.; Clemente, A.; Guadalupi, V.; Signorelli, D.; Tiseo, M.; et al. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: Prospective analysis from a multicentre observational trial by FICOG. Ther. Adv. Med. Oncol. 2020, 12, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Desai, A.; Gupta, R.; Advani, S.; Ouellette, L.; Kuderer, N.M.; Lyman, G.H.; Li, A. Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. Cancer 2021, 127, 1459–1468. [Google Scholar] [CrossRef] [PubMed]
- Kuderer, N.M.; Choueiri, T.K.; Shah, D.P.; Shyr, Y.; Rubinstein, S.M.; Rivera, D.R.; Shete, S.; Hsu, C.Y.; Desai, A.; de Lima Lopes, G., Jr.; et al. Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study. Lancet 2020, 395, 1907–1918. [Google Scholar] [CrossRef]
- Passamonti, F.; Cattaneo, C.; Arcaini, L.; Bruna, R.; Cavo, M.; Merli, F.; Angelucci, E.; Krampera, M.; Cairoli, R.; Della Porta, M.G.; et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study. Lancet Haematol. 2020, 7, e737–e745. [Google Scholar] [CrossRef]
- Di Giacomo, A.M.; Giacobini, G.; Gandolfo, C.; Lofiego, M.F.; Cusi, M.G.; Maio, M. Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix. Eur. J. Cancer 2021, 156, 119–121. [Google Scholar] [CrossRef] [PubMed]
- Sadoff, J.; Le Gars, M.; Shukarev, G.; Heerwegh, D.; Truyers, C.; de Groot, A.M.; Stoop, J.; Tete, S.; Van Damme, W.; Leroux-Roels, I.; et al. Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine. N. Engl. J. Med. 2021, 384, 1824–1835. [Google Scholar] [CrossRef] [PubMed]
- Thakkar, A.; Gonzalez-Lugo, J.D.; Goradia, N.; Gali, R.; Shapiro, L.C.; Pradhan, K.; Rahman, S.; Kim, S.Y.; Ko, B.; Sica, R.A.; et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021, 39, 1081–1090.e1082. [Google Scholar] [CrossRef]
- Desai, A.; Gainor, J.F.; Hegde, A.; Schram, A.M.; Curigliano, G.; Pal, S.; Liu, S.V.; Halmos, B.; Groisberg, R.; Grande, E.; et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat. Rev. Clin. Oncol. 2021, 18, 313–319. [Google Scholar] [CrossRef]
- Rubin, R. Influenza’s unprecedented low profile during COVID-19 pandemic leaves experts wondering what this flu season has in store. JAMA 2021, 326, 899–900. [Google Scholar] [CrossRef]
- European Centre for Disease Prevention and Control. Interim Public Health Considerations for the Provision of Additional COVID-19 Vaccine Doses. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/Interim-public-health-considerations-for-the-provision-of-additional-COVID-19-vaccine-doses.pdf (accessed on 5 May 2022).
- Joint Committee on Vaccination and Immunisation. JCVI Statement Regarding a COVID-19 Booster Vaccine Programme for Winter 2021 to 2022. Available online: https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-statement-regarding-a-covid-19-booster-vaccine-programme-for-winter-2021-to-2022 (accessed on 5 May 2022).
- Lazarus, R.; Baos, S.; Cappel-Porter, H.; Carson-Stevens, A.; Clout, M.; Culliford, L.; Emmett, S.R.; Garstang, J.; Gbadamoshi, L.; Hallis, B.; et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): A multicentre, randomised, controlled, phase 4 trial. Lancet 2021, 398, 2277–2287. [Google Scholar] [CrossRef] [PubMed]
- Toback, S.; Galiza, E.; Cosgrove, C.; Galloway, J.; Goodman, A.L.; Swift, P.A.; Rajaram, S.; Graves-Jones, A.; Edelman, J.; Burns, F.; et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2022, 10, 167–179. [Google Scholar] [CrossRef] [PubMed]
- Bartoszkiewicz, M.; Kufel-Grabowska, J.; Litwiniuk, M. Seasonal influenza vaccination among cancer patients during the COVID-19 pandemic in Poland. Contemp. Oncol. 2021, 25, 168–173. [Google Scholar] [CrossRef] [PubMed]
- Skyles, T.J.; Stevens, H.P.; Obray, A.M.; Jensen, J.L.; Miner, D.S.; Bodily, R.J.; Nielson, B.U.; Poole, B.D. Changes in attitudes and barriers to seasonal influenza vaccination from 2007 to 2023. J. Community Health 2023, 49, 207–217. [Google Scholar] [CrossRef]
- Su, Z.; Cheshmehzangi, A.; McDonnell, D.; da Veiga, C.P.; Xiang, Y.T. Mind the “vaccine fatigue”. Front. Immunol. 2022, 13, 839433. [Google Scholar] [CrossRef] [PubMed]
- Bengoa Terrero, C.; Bas Villalobos, M.; Rodriguez-Monino, A.P.; Lasheras Carbajo, M.D.; Perez-Villacastin, J.; Garcia Torrent, M.J.; Sanchez-Del-Hoyo, R.; Bengoa San Sebastian, E.; Garcia Lledo, A. Effect of primary care center characteristics, healthcare worker vaccination status and patient economic setting on patient influenza vaccination coverage rates. Vaccines 2023, 11, 1025. [Google Scholar] [CrossRef]
- World Health Organization. Vaccine Hesitancy: A Growing Challenge for Immunization Programme. Available online: https://www.who.int/news/item/18-08-2015-vaccine-hesitancy-a-growing-challenge-for-immunization-programmes (accessed on 22 September 2022).
- World Health Organization. Global Vaccine Action Plan 2011–2020. Available online: https://www.who.int/publications/i/item/global-vaccine-action-plan-2011-2020 (accessed on 22 September 2022).
- European Centre for Disease Prevention and Control. Let’s Talk about Hesitancy. Available online: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/lets-talk-about-hesitancy-vaccination-guide.pdf (accessed on 22 September 2022).
- Wumkes, M.L.; van der Velden, A.M.; van der Velden, A.W.; Stouthard, J.M.; Nijziel, M.R.; Westerman, M.; Beeker, A.; Meerveld-Eggink, A.; Rijkers, G.T.; Biesma, D.H. Influenza vaccination coverage in patients treated with chemotherapy: Current clinical practice. Neth. J. Med. 2013, 71, 472–477. [Google Scholar]
- Istituto Superiore di Sanità. 2023–2024 Recommendations for COVID-19 Vaccination. Available online: https://www.epicentro.iss.it/vaccini/vaccini-covid-19-raccomandazioni-23-24 (accessed on 18 March 2024). (In Italian).
- Ministero della Salute. COVID-19 Vaccination Campaign 2023/2024. Available online: https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?lingua=italiano&id=6110&area=nuovoCoronavirus&menu=vuoto (accessed on 18 March 2024). (In Italian)
- Ministero della Salute. Indications and Recommendations for the 2023/2024 Autumn/Winter Anti COVID-19 Vaccination Campaign. Available online: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2023&codLeg=96278&parte=1%20&serie=null (accessed on 18 March 2024). (In Italian)
- Ministero della Salute. Integration of the Indications and Recommendations for the 2023/2024 Autumn/Winter Anti COVID-19 Vaccination Campaign. Available online: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2023&codLeg=97783&parte=1%20&serie=null (accessed on 18 March 2024). (In Italian)
- Bonanni, P.; Steffen, R.; Schelling, J.; Balaisyte-Jazone, L.; Posiuniene, I.; Zatonski, M.; Van Damme, P. Vaccine co-administration in adults: An effective way to improve vaccination coverage. Hum. Vaccin. Immunother. 2023, 19, 2195786. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases, 14th ed.; Hall, E., Wodi, A.P., Hamborsky, J., Morelli, V., Schillie, S., Eds.; Public Health Foundation: Washington, DC, USA, 2021. [Google Scholar]
Barrier | Strategy |
---|---|
|
|
| |
|
|
|
|
| |
| |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bonanni, P.; Maio, M.; Beretta, G.D.; Icardi, G.; Rossi, A.; Cinieri, S. Improving Influenza Vaccination Coverage in Patients with Cancer: A Position Paper from a Multidisciplinary Expert Group. Vaccines 2024, 12, 420. https://doi.org/10.3390/vaccines12040420
Bonanni P, Maio M, Beretta GD, Icardi G, Rossi A, Cinieri S. Improving Influenza Vaccination Coverage in Patients with Cancer: A Position Paper from a Multidisciplinary Expert Group. Vaccines. 2024; 12(4):420. https://doi.org/10.3390/vaccines12040420
Chicago/Turabian StyleBonanni, Paolo, Michele Maio, Giordano D. Beretta, Giancarlo Icardi, Alessandro Rossi, and Saverio Cinieri. 2024. "Improving Influenza Vaccination Coverage in Patients with Cancer: A Position Paper from a Multidisciplinary Expert Group" Vaccines 12, no. 4: 420. https://doi.org/10.3390/vaccines12040420